Filtered By:
Vaccination: Pneomococcal Vaccine
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 3041 results found since Jan 2013.
Impact of methotrexate treatment on vaccines immunogenicity in adult rheumatological patients - Lessons learned from the COVID-19 pandemic
Biomed Pharmacother. 2023 Aug 3;165:115254. doi: 10.1016/j.biopha.2023.115254. Online ahead of print.ABSTRACTDespite the development of new biological and synthetic targeted therapies, methotrexate remains one of the most commonly used immunomodulatory drugs in rheumatology. However, its effect on the immunogenicity of vaccines has been studied only to a limited extent until recently, resulting in the lack of clear guidelines on the use of methotrexate during vaccination. Significant progress was made during the COVID-19 pandemic due to the dynamic development of research on vaccines, including patients with autoimmune inf...
Source: Herpes - August 5, 2023 Category: Infectious Diseases Authors: Jakub Wro ński Marzena Ciechomska Ewa Kuca-Warnawin Source Type: research
Modeling the impact of vaccination for the immunization Agenda 2030: Deaths averted due to vaccination against 14 pathogens in 194 countries from 2021 to 2030
Vaccine. 2023 Aug 1:S0264-410X(23)00854-X. doi: 10.1016/j.vaccine.2023.07.033. Online ahead of print.ABSTRACTBACKGROUND: The Immunization Agenda 2030 (IA2030) Impact Goal 1.1. aims to reduce the number of future deaths averted through immunization in the next decade. To estimate the potential impact of the aspirational coverage targets for IA2030, we developed an analytical framework and estimated the number of deaths averted due to an ambitious vaccination coverage scenario from 2021 to 2030 in 194 countries.METHOD: A demographic model was used to determine annual age-specific mortality estimates associated with vaccine c...
Source: Vaccine - August 3, 2023 Category: Allergy & Immunology Authors: Austin Carter William Msemburi So Yoon Sim Katy A M Gaythorpe Philipp Lambach Ann Lindstrand Raymond Hutubessy Source Type: research
Immune responses to SARS-CoV-2 infection and vaccination in children
Semin Immunol. 2023 Jun 20;69:101794. doi: 10.1016/j.smim.2023.101794. Online ahead of print.ABSTRACTDuring the three years since SARS-CoV-2 infections were first described a wealth of information has been gathered about viral variants and their changing properties, the disease presentations they elicit and how the many vaccines developed in record time protect from COVID-19 severe disease in different populations. A general theme throughout the pandemic has been the observation that children and young people in general fare well, with mild symptoms during acute infection and full recovery thereafter. It has also become cl...
Source: Seminars in Immunology - August 3, 2023 Category: Allergy & Immunology Authors: Petter Brodin Source Type: research
Modeling the impact of vaccination for the immunization Agenda 2030: Deaths averted due to vaccination against 14 pathogens in 194 countries from 2021 to 2030
Vaccine. 2023 Aug 1:S0264-410X(23)00854-X. doi: 10.1016/j.vaccine.2023.07.033. Online ahead of print.ABSTRACTBACKGROUND: The Immunization Agenda 2030 (IA2030) Impact Goal 1.1. aims to reduce the number of future deaths averted through immunization in the next decade. To estimate the potential impact of the aspirational coverage targets for IA2030, we developed an analytical framework and estimated the number of deaths averted due to an ambitious vaccination coverage scenario from 2021 to 2030 in 194 countries.METHOD: A demographic model was used to determine annual age-specific mortality estimates associated with vaccine c...
Source: Vaccine - August 3, 2023 Category: Allergy & Immunology Authors: Austin Carter William Msemburi So Yoon Sim Katy A M Gaythorpe Philipp Lambach Ann Lindstrand Raymond Hutubessy Source Type: research
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel
Blood Cancer J. 2023 Aug 1;13(1):116. doi: 10.1038/s41408-023-00879-7.ABSTRACTBispecific antibodies (BsAbs) are emerging as an important novel class of immunotherapeutic agents for the treatment of multiple myeloma (MM), and are set to be more widely used in clinical practice. However, this new class of therapies is associated with a distinct adverse event (AE) profile that includes cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, as well as AEs leading to increased infection risk such as cytopenias and hypogammaglobulinemia, and infections themselves. As preliminary data with this clas...
Source: Herpes - August 1, 2023 Category: Infectious Diseases Authors: Noopur Raje Kenneth Anderson Hermann Einsele Yvonne Efebera Francesca Gay Sarah P Hammond Alexander M Lesokhin Sagar Lonial Heinz Ludwig Philippe Moreau Krina Patel Karthik Ramasamy Maria-Victoria Mateos Source Type: research
Effectiveness of thirteen-valent pneumococcal conjugate vaccine to prevent serotype 3 invasive pneumococcal disease in Quebec in children, Canada
The objective was to estimate PCV13 effectiveness to prevent serotype 3 invasive pneumococcal disease in children aged less than 5 years, using 2010-2018 mandatory notification and laboratory surveillance data, an indirect cohort design and multivariate logistic regression models. A total of 29 cases of serotype 3 and 290 non-vaccine serotype cases as controls were analysed. Overall vaccine effectiveness (≥1 dose) was estimated at 59% [-39% to 88%]. During the first year after the last dose effectivness was 88% [47% to 97%] whereas no protection was observed thereafter. There was no trend towards increased effectiveness ...
Source: Vaccine - July 31, 2023 Category: Allergy & Immunology Authors: Genevi ève Deceuninck Nicholas Brousseau Brigitte Lefebvre Caroline Quach Bruce Tapiero Yen-Giang Bui Micha ël Desjardins Philippe De Wals Source Type: research
Addressing racial inequality and its effects on vaccination rate: A trial comparing a pharmacist and peer educational program (MOTIVATE) in diverse older adults
CONCLUSIONS: Both interventions significantly improved knowledge and trust toward vaccination and retained their effect 1 month after the program. The 2 effective community-based education models should be expanded to ensure timely and trusted information is available to educate older adults about vaccine-preventable diseases. Further research is encouraged to assess the long-term cost-effectiveness of these models' utilization on a larger scale. DISCLOSURES: Dr Schafer is an employee of Merck; however, at the time of the project, he was a professor at Thomas Jefferson University. The other authors have no conflicts of int...
Source: Herpes - July 31, 2023 Category: Infectious Diseases Authors: Katherine M Prioli Ayse Akincigil Tarlan Namvar Jocelyn Mitchell-Williams Jason J Schafer Renee C Cunningham Lynn Fields-Harris Megan McCoy Ronald Vertsman Ashley Guesnier Laura T Pizzi Source Type: research
Effectiveness of thirteen-valent pneumococcal conjugate vaccine to prevent serotype 3 invasive pneumococcal disease in Quebec in children, Canada
The objective was to estimate PCV13 effectiveness to prevent serotype 3 invasive pneumococcal disease in children aged less than 5 years, using 2010-2018 mandatory notification and laboratory surveillance data, an indirect cohort design and multivariate logistic regression models. A total of 29 cases of serotype 3 and 290 non-vaccine serotype cases as controls were analysed. Overall vaccine effectiveness (≥1 dose) was estimated at 59% [-39% to 88%]. During the first year after the last dose effectivness was 88% [47% to 97%] whereas no protection was observed thereafter. There was no trend towards increased effectiveness ...
Source: Vaccine - July 31, 2023 Category: Allergy & Immunology Authors: Genevi ève Deceuninck Nicholas Brousseau Brigitte Lefebvre Caroline Quach Bruce Tapiero Yen-Giang Bui Micha ël Desjardins Philippe De Wals Source Type: research
Spread of multidrug resistance in non-PCV13/PCV20 serotypes of Streptococcus pneumoniae: A cross-sectional study ten years after the introduction of pneumococcal conjugate vaccine in Japan
J Microbiol Immunol Infect. 2023 Jul 20:S1684-1182(23)00123-8. doi: 10.1016/j.jmii.2023.07.004. Online ahead of print.ABSTRACTTen years after the introduction of the pneumococcal conjugate vaccine (PCV) in Japan, the prevalence rates of non-PCV13 and non-PCV20 serotypes among pediatric pneumococcal isolates were 94.0% and 73.7%, respectively. The predominant non-PCV13/PCV20 serotypes (15A, 35B, and 23A) were mostly multidrug-resistant (≥80.5%), exhibiting non-susceptibility to penicillin.PMID:37517964 | DOI:10.1016/j.jmii.2023.07.004
Source: Journal of Microbiology, Immunology, and Infection - July 30, 2023 Category: Microbiology Authors: Mitsuyo Kawaguchiya Noriko Urushibara Meiji Soe Aung Nobuhide Ohashi Rika Takamatsu Sho Tsutida Masahiko Ito Nobumichi Kobayashi Source Type: research
Use of Information and Communication Technology Strategies to Increase Vaccination Coverage in Older Adults: A Systematic Review
CONCLUSIONS: Prevention programs using ICT tools could be effective in promoting immunizations among older adults.PMID:37515089 | DOI:10.3390/vaccines11071274
Source: Herpes - July 29, 2023 Category: Infectious Diseases Authors: Alessandra Buja Giulia Grotto Mustapha Taha Silvia Cocchio Vincenzo Baldo Source Type: research
Incremental effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia hospitalisation among Australian Indigenous children: A record linkage study
CONCLUSION: In this high-risk population, no statistically significant incremental effect of a PPV23 booster at 18-30 months was observed against hospitalised all-cause pneumonia or the more specific outcome of presumptive pneumococcal pneumonia. Confounding by indication may explain the slight trend towards an increased risk against all-cause pneumonia. Larger studies with better control of confounding are needed to further inform PPV23 vaccination.PMID:37507273 | DOI:10.1016/j.vaccine.2023.07.042
Source: Vaccine - July 28, 2023 Category: Allergy & Immunology Authors: Alamgir Kabir Deborah Randall Anthony T Newall Hannah C Moore Sanjay Jayasinghe Parveen Fathima Bette Liu Peter McIntyre Heather F Gidding Source Type: research
